GuidesJuly 27, 2026

The Peptide Acronym Glossary: API, RUO, COA, BAC Water, and More

A plain-English guide to the acronyms, units, regulatory labels, and chemistry terms that appear constantly in peptide discussions—including free base versus acetate.


FIELD GUIDE · 2026
API What is in it? Ingredient identity
COA What was tested? Analytical evidence
RUO How is it labeled? Intended-use language
503 Who compounded it? Regulatory pathway

The same four letters can describe chemistry, evidence, regulation, or community slang. Knowing which lane you are in prevents most of the confusion.

Peptide discussions have their own compressed language.

Some terms are formal pharmaceutical or regulatory concepts. Others are lab shorthand. A few are community slang that sound more official than they really are.

This guide separates those categories so you can translate a product page, a COA, or a forum post without giving the abbreviation more authority than it deserves.

The 60-second glossary

API: Active Pharmaceutical Ingredient

APIThe component intended to provide the pharmacological activity

In ordinary peptide conversation, people often use API to mean “the peptide itself” or “the raw powder.” That is directionally useful, but chemically incomplete.

FDA defines an active ingredient as a component intended to provide pharmacological activity or another direct effect on the body.1

The API is different from the finished product, which may also contain:

  • counterions such as acetate
  • stabilizers or bulking agents
  • water or residual solvents
  • preservatives
  • and other inactive ingredients

That is why a vial containing 10 mg of visible powder should not automatically be read as 10 mg of pure active peptide. “Raw powder” and “pure API” are not synonyms.

RUO: Research Use Only

RUOIntended-use language—not an approval or quality grade

In the peptide market, RUO usually appears beside “not for human consumption.” People also use “RUO vendor” as shorthand for a research-chemical seller.

The important distinction is that RUO is a label, not a vendor license or a legal product class.

FDA has repeatedly explained in warning letters that “research use only” language does not override other evidence showing that a seller actually intends a product for human drug use.2

So RUO does not mean:

  • FDA approved
  • manufactured under cGMP
  • independently tested
  • safe for human use
  • or automatically lawful regardless of how the product is marketed

The phrase has a defined regulatory role for certain research-stage in-vitro diagnostic products, but peptide sellers use it much more broadly.3

COA: Certificate of Analysis

COAA document reporting selected tests on a sample or batch

A COA should tell you what was tested, how it was tested, which sample or lot it represents, and what the laboratory reported.

A COA can support one or more claims about:

  • identity
  • purity
  • measured quantity
  • sterility
  • endotoxin
  • heavy metals
  • or other tested panels

But those panels are not interchangeable. A 99.5% purity result does not silently prove sterility, accurate fill, low endotoxin, or strong chain of custody.

The right question is not merely “Does it have a COA?” It is:

What does this particular certificate establish, and can it be connected to the current product and batch?

You can inspect source-linked records in the PeptideBenchmark COA Database or read the full guide to how to read a peptide COA.

503A and 503B

503A / 503BSections of the Federal Food, Drug, and Cosmetic Act

“503” is often used loosely to mean a legitimate compounding pharmacy, but 503A and 503B describe different statutory pathways.

503A generally covers qualifying compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. It is ordinarily tied to a valid prescription for an identified individual patient.

503B covers registered outsourcing facilities. These facilities may compound with or without patient-specific prescriptions, must comply with federal cGMP requirements, report specified product information, and are inspected by FDA on a risk-based schedule.4

Two cautions:

  1. A compounded drug is not the same as an FDA-approved drug.
  2. A website merely saying “503A” or “503B” does not prove that the seller, facility, or specific product satisfies the applicable requirements.

FDA maintains a public list of registered outsourcing facilities.

PIP: Post-Injection Pain

PIPCommunity shorthand for discomfort after an injection

The term may describe stinging, soreness, redness, swelling, or another local reaction. It describes an experience, not its cause.

PIP is not a quality test or a diagnosis. A local reaction could have multiple explanations, and the acronym should not be used to normalize a persistent, worsening, or systemic problem.

cGMP: Current Good Manufacturing Practice

cGMPA regulated system of manufacturing controls

The “current” matters: the standard requires up-to-date systems for designing, monitoring, controlling, documenting, and investigating pharmaceutical manufacturing.

FDA describes cGMP as the main regulatory standard for assuring pharmaceutical quality, including identity, strength, quality, and purity.5

It is much broader than sending one vial to a laboratory. It covers systems such as:

  • facility and process controls
  • qualified materials and suppliers
  • written procedures
  • deviation investigations
  • quality management
  • and reliable laboratory operations

This is why cGMP-grade on a storefront should not be treated as a self-authenticating badge. Ask which facility, which scope, and what verifiable evidence supports the claim.

Also note the regulatory nuance: qualifying 503A compounding is exempt from federal drug cGMP requirements, while 503B outsourcing facilities are not.4

GLP-1 and “GLP-3”

GLP-1 / GLP-3One formal term and one informal market label

GLP-1 is glucagon-like peptide-1. “GLP-3” is not the formal name of a recognized third GLP hormone or drug class.

The more accurate shorthand is:

  • Semaglutide: GLP-1 receptor agonist
  • Tirzepatide: dual GIP and GLP-1 receptor agonist
  • Retatrutide: triple GIP, GLP-1, and glucagon receptor agonist

Retatrutide is therefore commonly called a triple agonist. The peer-reviewed clinical literature describes those three receptor targets directly.6

Some research-market vendors use names such as GLP-3, 3G, or GLP-3RT to avoid spelling out retatrutide. Read those as storefront aliases—not scientific classification.

TRT: Testosterone Replacement Therapy

TRTTestosterone replacement therapy

TRT appears frequently in the same performance, longevity, and hormone-optimization conversations as peptides, but testosterone is a steroid hormone—not a peptide.

The overlap is cultural and clinical-discussion related, not chemical. TRT is prescription medical treatment with its own indications, monitoring, risks, and regulatory context.

n=1

n=1A sample size of one

Online, people often use it to mean “this was only my personal experience.” That is a fair warning about limited generalizability.

But a casual self-report is not automatically a rigorous N-of-1 trial. Formal N-of-1 designs may use prospectively planned treatment periods, repeated measurements, controls, crossover, randomization, or blinding.7

The useful translation is:

Interesting observation; not enough to estimate what usually happens to other people.

BAC or BW: Bacteriostatic Water

BAC / BWBacteriostatic Water for Injection

A U.S. Bacteriostatic Water for Injection product is sterile water containing a bacteriostatic preservative—commonly 0.9% benzyl alcohol—and is supplied as a multi-dose diluent.[^bac]

Two details often get lost:

  • BW can be ambiguous because people may also mean plain sterile water.
  • Bacteriostatic water is not automatically the correct diluent for every product or population. Approved product instructions specify the appropriate diluent and handling.

The presence of water, a preserved multi-dose vial, or the word “sterile” also does not validate an unrelated research peptide.

IU: International Units

IUA standardized measure of biological activity

IU is common around hormones and biologic products such as growth hormone, hCG, and insulin. It is not a universal mass unit.

An IU-to-milligram conversion is substance-specific because the unit is tied to a defined biological standard or potency. You cannot convert IU to mg without knowing the particular substance and reference standard.

Recon: Reconstitution

ReconReconstitution

Reconstitution means adding a specified liquid to a dry or lyophilized product to form a solution or suspension.

Lyophilized means freeze-dried. “Recon” is conversational shorthand, not a universal recipe: the diluent, volume, handling, storage, and usable period depend on the actual product instructions.

Free base versus acetate

This sounds like a purity comparison. Usually, it is a chemical-form and labeling-basis question.

Free base

The active moiety described without the salt-forming counterion. For peptides with many ionizable groups, “free base” can be an oversimplification because charge state changes with pH.

Acetate salt

The peptide is associated with acetate counterions. Acetate contributes mass and may affect handling, solubility, or stability, but it is not automatically an impurity or a sign of inferior quality.

Many synthetic peptides are isolated as salts. During synthesis and purification, positively charged sites on the peptide need counterions; common forms include acetate and trifluoroacetate.

FDA’s salt-naming guidance distinguishes the active moiety—the part responsible for pharmacological action—from the portion that makes the substance a salt. For approved products following this policy, strength is generally expressed in terms of the active moiety while the specific salt form is also disclosed.8

In the research market, labels are not always that clear. If one listing says 10 mg free base and another says 10 mg acetate, ask:

  1. Is the stated mass based on the peptide’s active moiety or total salt mass?
  2. Was net peptide content measured, or is the number only a nominal fill?
  3. Does the COA report counterion content, water content, or peptide content?
  4. Are you comparing equivalent chemical forms and analytical methods?
Bottom line: acetate does not mean “diluted peptide,” and free base does not mean “purer peptide.” Without a clearly stated measurement basis, the label alone cannot settle how much active peptide is present.

Bonus lab-report shorthand

These terms frequently appear beside COAs:

HPLC / UHPLC

High-performance liquid chromatography or ultra-high-performance liquid chromatography. These methods separate components in a sample and can support a reported purity profile. A dominant peak does not by itself establish every aspect of identity, content, or safety.

LC-MS

Liquid chromatography–mass spectrometry. It combines separation with mass analysis and can support identity or impurity characterization. The exact claim depends on the method and data shown.

TFA

Trifluoroacetic acid or a trifluoroacetate counterion, depending on context. TFA is commonly encountered in peptide synthesis and purification. A report should distinguish residual TFA testing from merely naming a salt form.

EU/mL

Endotoxin units per milliliter. This is an activity-based unit used in bacterial endotoxin testing. Endotoxin testing is separate from sterility testing.

Four translations worth remembering

“COA available”Which batch, which panels, which methods, and can the source be checked?
“RUO”Intended-use wording—not FDA approval and not proof of manufacturing quality.
“cGMP-grade”A claim that needs a named facility, defined scope, and verifiable support.
“10 IU”A biological-activity measure that cannot be converted without the substance-specific standard.

Final takeaway

The most important skill is not memorizing every abbreviation. It is identifying what kind of statement the abbreviation represents:

  • chemistry: API, free base, acetate, TFA
  • analytical evidence: COA, HPLC, LC-MS, EU/mL
  • regulation and manufacturing: RUO, 503A, 503B, cGMP
  • units and preparation language: IU, BAC water, recon
  • community shorthand: PIP, n=1, GLP-3

Once those lanes are separated, product pages and peptide discussions become much easier to read critically.

Primary sources

Footnotes

  1. FDA Drugs@FDA Glossary of Terms.

  2. FDA warning letter to Synthetix Inc. / Helix Chemical Supply.

  3. FDA: Bioresearch Monitoring Inspections in Vitro Diagnostic Devices.

  4. FDA: FD&C Act Provisions That Apply to Human Drug Compounding. 2

  5. FDA: Facts About the Current Good Manufacturing Practice.

  6. Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity, PubMed.

  7. NIH Research Methods Resources: Personalized or N-of-1 Trials.

  8. FDA: Naming of Drug Products Containing Salt Drug Substances.

Common questions

What does RUO mean on a peptide product?

RUO means Research Use Only. In the peptide market it commonly appears beside “not for human consumption,” but the wording is not FDA approval, a manufacturing standard, or a legal shield when a product is actually promoted for human use.

Is GLP-3 a recognized medical drug class?

No. GLP-3 is informal market shorthand often used for retatrutide or triple-agonist products. Retatrutide acts at the GIP, GLP-1, and glucagon receptors; it is not a third version of GLP.

Does peptide acetate mean the product is lower quality than free base?

No. Acetate identifies a counterion or salt form and does not by itself establish purity, potency, or manufacturing quality. Meaningful comparison requires knowing whether the stated mass refers to the active peptide moiety or the complete salt and what the analytical report actually measured.

Does a COA prove that a peptide is sterile?

Only if the attributable certificate includes a sterility test. Purity, identity, net content, endotoxin, heavy-metals, and sterility testing answer different questions and should not be treated as interchangeable.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

Section 503A generally covers qualifying patient-specific compounding by licensed pharmacists, pharmacies, or physicians. Section 503B covers registered outsourcing facilities, which may compound without patient-specific prescriptions and remain subject to federal CGMP requirements.